Ovid Therapeutics (OVID) Total Non-Current Liabilities (2018 - 2022)

Ovid Therapeutics' Total Non-Current Liabilities history runs 5 years deep, the most recent figure standing at $26.1 million for Q1 2022.

• Quarterly Total Non-Current Liabilities rose 59.67% year-over-year to $26.1 million in Q1 2022, while the trailing twelve-month figure through Mar 2022 was $26.1 million (up 59.67% YoY) and the FY2021 annual result came in at $14.8 million, down 54.18% from the prior year.
• Total Non-Current Liabilities was $26.1 million for Q1 2022 at Ovid Therapeutics, up from $14.8 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $32.3 million in Q4 2020 and bottomed at $8.8 million in Q4 2018.
• A 5-year average of $15.2 million and a median of $11.1 million in 2019 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2020 — Total Non-Current Liabilities surged 198.46% — and 2021, when it sank 64.0%.
• Ovid Therapeutics' Total Non-Current Liabilities stood at $8.8 million in 2018, then increased by 22.34% to $10.8 million in 2019, then surged by 198.46% to $32.3 million in 2020, then tumbled by 54.18% to $14.8 million in 2021, then soared by 76.37% to $26.1 million in 2022.
• Business Quant data shows OVID's Total Non-Current Liabilities at $26.1 million in Q1 2022, $14.8 million in Q4 2021, and $10.1 million in Q3 2021.